ARQT insider buying and SEC filings, explained
Arcutis Biotherapeutics, Inc. · CIK 1787306
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$1.2M
Planned sales (10b5-1)
$11.9M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Oct 15, 2026 | Planned (10b5-1) | Howard G. Welgus (Director) sold 4,728 shares at $26.93 ($127K), marked as a 10b5-1 plan trade. Holdings down 12% to 35,207 shares. | SEC filing Filed Oct 19, 2026, 4:49 PM ET |
| Sep 16, 2026 | Planned (10b5-1) | Masaru Matsuda (Chief Legal Officer) sold 3,674 shares at about $25.00 ($92K), marked as a 10b5-1 plan trade. Holdings down 3% to 112,508 shares. | SEC filing Filed Sep 18, 2026 |
| Sep 15, 2026 | Planned (10b5-1) | Howard G. Welgus (Director) sold 4,730 shares at $24.18 ($114K), marked as a 10b5-1 plan trade. Holdings down 12% to 35,841 shares. | SEC filing Filed Sep 17, 2026 |
| Sep 8, 2026 | Planned (10b5-1) | Masaru Matsuda (Chief Legal Officer) sold 9,989 shares at about $25.03 ($250K), marked as a 10b5-1 plan trade. Holdings down 8% to 116,182 shares. | SEC filing Filed Sep 10, 2026 |
| Aug 19, 2026 | Sale | Patrick Burnett (Chief Medical Officer) sold 1,697 shares at $27.00 ($46K). Holdings down 1% to 117,592 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Aug 21, 2026 |
| Aug 17, 2026 | Planned (10b5-1) | Howard G. Welgus (Director) sold 4,730 shares at about $26.18 ($124K), marked as a 10b5-1 plan trade. Holdings down 11% to 36,475 shares. | SEC filing Filed Aug 19, 2026 |
| Aug 3, 2026 | Planned (10b5-1) | Patrick Burnett (Chief Medical Officer) sold 955 shares at about $26.12 ($25K), marked as a 10b5-1 plan trade. Holdings down 1% to 119,289 shares. | SEC filing Filed Aug 5, 2026 |
| Aug 3, 2026 | Planned (10b5-1) | Masaru Matsuda (Chief Legal Officer) sold 1,230 shares at about $26.12 ($32K), marked as a 10b5-1 plan trade. Holdings down 1% to 126,171 shares. | SEC filing Filed Aug 5, 2026 |
| Aug 3, 2026 | Planned (10b5-1) | Todd Watanabe (CEO and Director) sold 4,375 shares at about $26.12 ($114K), marked as a 10b5-1 plan trade. Holdings down 1% to 717,203 shares. | SEC filing Filed Aug 5, 2026 |
| Jul 15, 2026 | Planned (10b5-1) | Howard G. Welgus (Director) sold 4,730 shares at $26.91 ($127K), marked as a 10b5-1 plan trade. Holdings down 11% to 37,109 shares. | SEC filing Filed Jul 17, 2026 |
| Jun 15, 2026 | Planned (10b5-1) | Sue-Jean Lin (Director) sold 4,946 shares at about $24.38 ($121K), marked as a 10b5-1 plan trade. Holdings down 15% to 27,567 shares. | SEC filing Filed Jun 17, 2026 |
| Jun 15–17, 2026 | Planned (10b5-1) | Howard G. Welgus (Director) sold 4,731 shares between Jun 15 and Jun 17 at about $24.58 ($116K), marked as a 10b5-1 plan trade. Holdings down 11% to 37,743 shares. | SEC filing Filed Jun 17, 2026 |
| May 11, 2026 | Planned (10b5-1) | Latha Vairavan (CFO) sold 435 shares at $21.05 ($9K), marked as a 10b5-1 plan trade. Holdings down 1% to 85,978 shares. | SEC filing Filed May 13, 2026 |
| May 11, 2026 | Planned (10b5-1) | Patrick Burnett (Chief Medical Officer) sold 222 shares at $21.05 ($5K), marked as a 10b5-1 plan trade. Holdings down <1% to 120,244 shares. | SEC filing Filed May 13, 2026 |
| May 4, 2026 | Planned (10b5-1) | Latha Vairavan (CFO) sold 1,341 shares at about $23.61 ($32K), marked as a 10b5-1 plan trade. Holdings down 2% to 86,413 shares. | SEC filing Filed May 6, 2026 |
| May 4, 2026 | Planned (10b5-1) | Todd Watanabe (CEO and Director) sold 3,172 shares at about $23.61 ($75K), marked as a 10b5-1 plan trade. Holdings down <1% to 720,755 shares. | SEC filing Filed May 6, 2026 |
| May 4, 2026 | Planned (10b5-1) | Masaru Matsuda (Chief Legal Officer) sold 8,256 shares at about $23.31 ($192K), marked as a 10b5-1 plan trade. Holdings down 6% to 126,689 shares. | SEC filing Filed May 6, 2026 |
| May 4, 2026 | Planned (10b5-1) | Patrick Burnett (Chief Medical Officer) sold 684 shares at about $23.61 ($16K), marked as a 10b5-1 plan trade. Holdings down 1% to 120,466 shares. | SEC filing Filed May 6, 2026 |
| May 1, 2026 | Planned (10b5-1) | Howard G. Welgus (Director) sold 7,144 shares at about $22.99 ($164K), marked as a 10b5-1 plan trade. Holdings down 18% to 32,600 shares. | SEC filing Filed May 5, 2026 |
| Apr 1, 2026 | Planned (10b5-1) | Howard G. Welgus (Director) sold 10,000 shares at about $23.88 ($239K), marked as a 10b5-1 plan trade. Holdings down 20% to 39,744 shares. | SEC filing Filed Apr 3, 2026 |
| Mar 2, 2026 | Planned (10b5-1) | Keith R Leonard (Director) sold 39,272 shares at about $25.39 ($997K), marked as a 10b5-1 plan trade. Holdings down 64% to 22,123 shares. | SEC filing Filed Mar 4, 2026 |
| Mar 2, 2026 | Planned (10b5-1) | Howard G. Welgus (Director) sold 10,000 shares at about $25.65 ($257K), marked as a 10b5-1 plan trade. Holdings down 17% to 49,744 shares. | SEC filing Filed Mar 4, 2026 |
| Mar 2, 2026 | Planned (10b5-1) | Larry Todd Edwards (Chief Commercial Officer) sold 3,687 shares at about $25.18 ($93K), marked as a 10b5-1 plan trade. Holdings down 2% to 175,178 shares. | SEC filing Filed Mar 3, 2026 |
| Mar 2, 2026 | Planned (10b5-1) | Todd Watanabe (CEO and Director) sold 37,349 shares at about $25.18 ($941K), marked as a 10b5-1 plan trade. Holdings down 5% to 785,957 shares. | SEC filing Filed Mar 3, 2026 |
| Feb 27–Mar 2, 2026 | Planned (10b5-1) | Masaru Matsuda (Chief Legal Officer) sold 12,058 shares between Feb 27 and Mar 2 at about $26.03 ($314K), marked as a 10b5-1 plan trade. Holdings down 8% to 136,932 shares. | SEC filing Filed Mar 3, 2026 |
| Mar 2, 2026 | Planned (10b5-1) | Latha Vairavan (CFO) sold 2,853 shares at about $25.18 ($72K), marked as a 10b5-1 plan trade. Holdings down 3% to 87,754 shares. | SEC filing Filed Mar 3, 2026 |
| Mar 2, 2026 | Planned (10b5-1) | Patrick Burnett (Chief Medical Officer) sold 6,287 shares at about $25.18 ($158K), marked as a 10b5-1 plan trade. Holdings down 5% to 121,150 shares. | SEC filing Filed Mar 3, 2026 |
| Feb 2, 2026 | Planned (10b5-1) | Masaru Matsuda (Officer) sold 40,638 shares at about $25.28 ($1.0M), marked as a 10b5-1 plan trade. Holdings down 27% to 110,003 shares. | SEC filing Filed Feb 4, 2026 |
| Feb 2–4, 2026 | Planned (10b5-1) | Patrick Burnett (Chief Medical Officer) sold 13,469 shares between Feb 2 and Feb 4 at about $25.73 ($346K), marked as a 10b5-1 plan trade. Holdings down 14% to 80,651 shares. | SEC filing Filed Feb 4, 2026 |
| Feb 2, 2026 | Planned (10b5-1) | Todd Watanabe (CEO and Director) sold 19,833 shares at about $25.50 ($506K), marked as a 10b5-1 plan trade. Holdings down 3% to 721,306 shares. | SEC filing Filed Feb 4, 2026 |
| Feb 2, 2026 | Planned (10b5-1) | Latha Vairavan (CFO) sold 1,320 shares at about $25.50 ($34K), marked as a 10b5-1 plan trade. Holdings down 2% to 63,607 shares. | SEC filing Filed Feb 4, 2026 |
| Feb 2, 2026 | Planned (10b5-1) | Howard G. Welgus (Director) sold 10,000 shares at about $25.05 ($251K), marked as a 10b5-1 plan trade. Holdings down 14% to 59,744 shares. | SEC filing Filed Feb 4, 2026 |
| Feb 2, 2026 | Planned (10b5-1) | Larry Todd Edwards (Chief Commercial Officer) sold 2,052 shares at about $25.50 ($52K), marked as a 10b5-1 plan trade. Holdings down 1% to 148,865 shares. | SEC filing Filed Feb 4, 2026 |
| Jan 5, 2026 | Planned (10b5-1) | Patrick Burnett (Chief Medical Officer) sold 2,490 shares at about $28.98 ($72K), marked as a 10b5-1 plan trade. Holdings down 3% to 94,120 shares. | SEC filing Filed Jan 7, 2026 |
| Jan 2, 2026 | Planned (10b5-1) | Howard G. Welgus (Director) sold 10,000 shares at about $28.96 ($290K), marked as a 10b5-1 plan trade. Holdings down 13% to 69,744 shares. | SEC filing Filed Jan 6, 2026 |
| Dec 31, 2025 | Planned (10b5-1) | Patrick Burnett (Chief Medical Officer) sold 1,697 shares at about $29.21 ($50K), marked as a 10b5-1 plan trade. Holdings down 2% to 96,610 shares. | SEC filing Filed Jan 2, 2026 |
| Dec 15, 2025 | Planned (10b5-1) | Patrick Burnett (Chief Medical Officer) sold 11,500 shares at about $28.94 ($333K), marked as a 10b5-1 plan trade. Holdings down 10% to 98,307 shares. | SEC filing Filed Dec 17, 2025 |
| Dec 1, 2025 | Planned (10b5-1) | Howard G. Welgus (Director) sold 10,000 shares at about $30.21 ($302K), marked as a 10b5-1 plan trade. Holdings down 11% to 79,744 shares. | SEC filing Filed Dec 3, 2025 |
| Dec 1, 2025 | Planned (10b5-1) | Masaru Matsuda (Officer) sold 1,657 shares at $30.23 ($50K), marked as a 10b5-1 plan trade. Holdings down 1% to 150,641 shares. | SEC filing Filed Dec 3, 2025 |
| Nov 21–24, 2025 | Planned (10b5-1) | Todd Watanabe (CEO and Director) sold 50,000 shares between Nov 21, 2025 and Nov 24, 2025 at about $30.35 ($1.5M), marked as a 10b5-1 plan trade. Holdings down 6% to 740,537 shares. | SEC filing Filed Nov 24, 2025 |
| Nov 20, 2025 | Sale | Halley E Gilbert (Director) sold 16,532 shares at about $27.55 ($455K). Holdings down 43% to 22,123 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 21, 2025 |
| Nov 19, 2025 | Planned (10b5-1) | Masaru Matsuda (Officer) sold 2,550 shares at about $28.29 ($72K), marked as a 10b5-1 plan trade. Holdings down 2% to 151,476 shares. | SEC filing Filed Nov 21, 2025 |
| Nov 13, 2025 | Planned (10b5-1) | Neha Krishnamohan (Director) sold 40,504 shares at about $23.20 ($940K), marked as a 10b5-1 plan trade. Holdings down 65% to 22,123 shares. | SEC filing Filed Nov 17, 2025 |
| Nov 6, 2025 | Sale | Larry Todd Edwards (Chief Commercial Officer) sold 29,131 shares at about $25.16 ($733K). Holdings down 16% to 150,193 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 10, 2025 |
| Nov 6, 2025 | Planned (10b5-1) | Patrick Burnett (Chief Medical Officer) sold 17,250 shares at about $24.18 ($417K), marked as a 10b5-1 plan trade. Holdings down 15% to 98,325 shares. | SEC filing Filed Nov 10, 2025 |
| Nov 3, 2025 | Planned (10b5-1) | Latha Vairavan (CFO) sold 88 shares at about $24.72 ($2K), marked as a 10b5-1 plan trade. Holdings down <1% to 64,927 shares. | SEC filing Filed Nov 5, 2025 |
| Nov 3, 2025 | Planned (10b5-1) | Todd Watanabe (CEO and Director) sold 11,547 shares at about $24.71 ($285K), marked as a 10b5-1 plan trade. Holdings down 1% to 794,893 shares. | SEC filing Filed Nov 5, 2025 |
| Nov 3, 2025 | Planned (10b5-1) | Howard G. Welgus (Director) sold 10,000 shares at about $25.27 ($253K), marked as a 10b5-1 plan trade. Holdings down 10% to 89,744 shares. | SEC filing Filed Nov 5, 2025 |
| Nov 3, 2025 | Planned (10b5-1) | Masaru Matsuda (Officer) sold 7,208 shares at about $24.71 ($178K), marked as a 10b5-1 plan trade. Holdings down 4% to 154,026 shares. | SEC filing Filed Nov 5, 2025 |
| Nov 3–5, 2025 | Planned (10b5-1) | Patrick Burnett (Chief Medical Officer) sold 6,486 shares between Nov 3, 2025 and Nov 5, 2025 at about $24.12 ($156K), marked as a 10b5-1 plan trade. Holdings down 6% to 98,325 shares. | SEC filing Filed Nov 5, 2025 |
35 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow ARQT in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.